<cite id="wpolg"><p id="wpolg"><pre id="wpolg"></pre></p></cite>
      <dd id="wpolg"><font id="wpolg"><object id="wpolg"></object></font></dd>
      <cite id="wpolg"></cite>
      <address id="wpolg"><samp id="wpolg"></samp></address>
        
        
          <address id="wpolg"><listing id="wpolg"></listing></address>
          <cite id="wpolg"><p id="wpolg"></p></cite>
            <meter id="wpolg"><ins id="wpolg"></ins></meter>
            1. 人琴棋牌

              home
              • History

              History

              History

              1915

              Company Founder:Eikuma Koba
              Company Founder:
              Eikuma Koba

              Eikuma Koba signed an agreement with Mulford Laboratories in the US, founding Maruho Shoten in the Doshomachi area of Osaka

              1920

              Maruho Shoten(1920)
              Maruho
              Shoten(1920)

              Maruho Shoten became a limited partnership

              1923

              Contract signed with DR. KADE Pharmazeutische Fabrik GmbH, a German pharmaceutical manufacturer, making Maruho exclusive distributor in Japan

              1939

              Name changed to Maruho Shoten Co., Ltd.

              1943

              Maruho was merged with Wakyo Pharmaceuticals by government order

              1949

              Jiro Takagi

              Maruho Shoten Co., Ltd. re-established on October 13

              1952

              Import / marketing contract with Luitpold-Werk Chemischpharmazeutische Fabrik

              1963

              Oyodo Research Laboratories set up (active until 1972)

              Oyodo Plant completed (active until 1967)

              1965

              Current name adopted: Maruho Co., Ltd.

              1967

              Shin-Oyodo Plant completed (active until 1972)

              1972

              Hikone Plant completed.
              Hikone Plant completed.

              Hikone Plant completed, Shin-Oyodo Plant renovated and became Oyodo Research Laboratories(active until 1998)

              1983

              Munich Representative Office established(active until 2006)

              1997

              Head office moved to the current location in Osaka

              1998

              Drug Development Laboratories
              Drug Development
              Laboratories

              Established Central Research and Development Laboratories (the current Kyoto R&D Center Drug Development Laboratories) in Kyoto, to include all Maruho laboratories

              2002

              Announced Long-Term Vision 2002, "Global Boutique Company for Dermatology"

              Established Maruho UK Office in Edinburgh (active until 2003)

              2006

              Drug Discovery Research Laboratories
              Drug Discovery Research
              Laboratories

              Established Drug Discovery Research Laboratories at the Kyoto R&D Center

              Opened London Office (active until 2012)

              2008

              Opened Düsseldorf Representative Office (active until 2013)

              2009

              Opened Tokyo Development Office

              Opened New York Office(active until 2011)

              2010

              Nagahama Plant completed

              2011

              Announced Long-Term Vision 2011, "Excellence in Dermatology"

              Established Maruho North America Inc. (MNAI) as a wholly owned subsidiary (active until 2015)

              2012

              Acquired Cutanea Life Sciences, Inc. (Cutanea) in the US as a wholly owned subsidiary

              Established Maruho Europe Ltd. (MEL) as a wholly owned subsidiary (active until 2015)

              2013

              Established Maruho Deutschland GmbH as a wholly owned subsidiary

              Acquired Maruho Hatsujyo Kogyo Co., Ltd. as a subsidiary through share acquisition

              2014

              Established Tateyama Pharmacentical Factory Co., Ltd. as a subsidiary

              2015

              Integrated MNAI into Cutanea

              2016

              Maruho Co., Ltd. And Maruho’s Founders, the Takagi Family, jointly established the Maruho Takagi Dermatology Foundation. (From August it was certified as a Public Interest Incorporated Foundation by the Japanese Government)

              Major Products

              1951-1977 Agent for asthma Asthmolysin
              1953-2017 Anti-hemorrhoidal preparation Posterisan
              1954-2001 Non-specific desensitizing agent Paspat Percutaneous Injection
              1954- Anticoagulant and blood circulation promotion agent Hirudoid
              1957-1994 Asthmolysin Capsules, additional formulation of Asthmolysin
              1959-2003 High-potency multiple digestive enzyme preparation Combizym
              1960-2001 Non-specific desensitizing agent Paspat Intracutaneous Injection
              1962- Agent for dermal disease Eksalb
              1965- Posterisan forte Ointment , additional formulation of Posterisan
              1968-2002 Asthmolysin Suppository, additional formulation of Asthmolysin
              1968-2006 Transdermal multiple anti-inflammatory Mobilat Ointment
              1984-1993 Articular cartilage protective agent Arteparon
              1986- Topical cortical hormone Voalla Ointment and Voalla Cream
              1987-2000 Disposable dermal trephine Dispopunch
              1988-2008 Anti-inflammatory/fever-reducing analgesic Minalfen Tablets
              1990- Additional indication of asteatosis approved for Hirudoid; efficacy classification changed to "blood-flow accelerative/skin-moisturizing agent"
              1992-2006 Recombinant interferon gamma Biogamma Injection 200
              1996- Hirudoid Soft, additional formulation of Hirudoid
              1996-2017 Joint function improving agent Hyalos
              1996- Posterisan F Suppository, additional formulation of Posterisan
              1998-2017 Transdermal therapeutic system bronchodilator Hokunalin Tape
              1999- Non-chemical debriding agent Bromelain Ointment
              2000- Anti-virus agent Casal Cream
              2000-2014 Natural skincare series 2e
              2001- Hirudoid Lotion, additional formulation of Hirudoid
              Agent for keratosis such as psoriasis vulgaris Oxarol Ointment
              2005- Oral penem antibiotic Farom Tablets and Farom Dry Syrup for Pediatric Use
              2006- Anthelmintic (anti-parasitic) STROMECTOL Tablets
              Oral allylamine antifungal agent Nedoril Tablets
              2007- Local anesthetic patch Penles
              Oxarol Lotion, additional formulation of Oxarol
              2008- Agent for pressure ulcers/skin ulcers Iodocoat Ointment
              Anti-herpes virus agent Famvir Tablets
              Additional indication of palmoplantar pustulosis for Oxarol formulations
              Farom Tablets and Farom Dry Syrup for Pediatric Use retained marketing approval
              2009- Antifungal agents Astat Cream, Astat Solution, and Astat Ointment retained marketing approval
              2010- Pressure ulcers/skin ulcers treatment Actosin Ointment
              2011- Farom Dry Syrup for Pediatric Use Additional 0.5g sachet
              2011-2014 Natural skincare series for infants 2e Baby Plus
              2012- Additional indication of pain following removal of molluscum contagiosum approved for Penles Tape
              2013- Additional indication of herpes simplex approved for Famvir Tablets
              Additional indication of pain relief in laser irradiation treatment of the skin for Penles Tape
              2014- Anti-atopic dermatitis agent Protopic Ointment 0.1% and Protopic Ointment 0.03% for Pediatric Use (2011.4-2014.3 Sales promotion olny)
              Skincare series iniks
              2015- Human anti-human IL-17A monoclonal antibody Cosentyx
              Acne vulgaris treatment agent BEPIO Gel
              2016- Quinolone anti-microbial topical treatment Zebiax Lotion Agent for psoriasis vulgaris Marduox Ointment
              Acne vulgaris treatment agent Differin Gel
              Infantile hemangioma treatment Hemangiol Syrup for Pediatric
              Acne vulgaris treatment agent Epiduo Gel
              2017- Skincare iniks UV Protection and iniks skincare kit
              Topical scalp psoriasis treatment Comclo Shampoo
              Epiduo Gel retained marketing approval
              Anti-herpes virus agent Amenalief Tablets
              Protopic Ointment retained marketing approval
              2018- in vitro diagnostic DermaQuick VZV
              skincare iniks skincare trinity kit and Cleansing Emulsion
              Reduction of Malodor Generated in Cancerous Cutaneous Ulcers Treatment Rozex Gel retained marketing approval
              Blood-flow accelerative/skin-moisturizing agent Hirudoid Foam
              Differin Gel retained marketing approval

              Page top
              人琴棋牌